Ken Londoner

Bioelectronic Medicine

Technology and medicine have gone hand and hand for many years. Consistent advances in the medical fields have saved millions of lives and improved many others. Medical technology is a broad field where innovation plays a crucial role in sustaining health. Areas like biotechnology, pharmaceuticals, information technology, the development of medical devices and equipment, and more have all made significant contributions to improving the health of people all around the world. More recently, there has been increasing interest in developing bioelectronic medicine that modulates the peripheral nervous system. Here, Ken Londoner, founder of BioSig Technologies, a privately held medical technology company developing and commercializing a new system to more accurately treat patients suffering from Atrial Fibrillation, will tell us more about this revolutionary field.


Bioelectronic medicine is a new approach to treating and diagnosing disease and injury, using device technology to read and modulate the electrical activity within the body’s nervous system, opening new doors to real-time diagnostics and treatment options for patients. One of the exciting aspects of bioelectronic medicine is its potential to supplement and even replace drugs, including their cost and often debilitating side effects. Ken Londoner, Chairman and CEO of BioSig Technologies believes their unique technology can play a key role in providing better tools for doctors who are treating potentially deadly arrhythmias. By providing clearer biomedical signals, the advanced signal processing capabilities can help clinicians to better understand patterns and how to change them to treat, or even prevent, diseases.

Bioelectronic medicine promises to bring new insights into the diagnosis and treatment of diseases and conditions as varied as cancer, rheumatoid arthritis, inflammatory bowel disease, obesity, diabetes, asthma, paralysis, blindness, bleeding, ischemia, organ transplantation, cardiovascular disease, neurodegenerative diseases, and others. Over the past years, Ken Londoner and his lab have worked on developing a number of electronic materials, device designs and manufacturing techniques for devices with a broad range of options that offer the potential to address unmet medical needs. BioSig Technologies designed and developed a new system called PURE EP System, meant to more accurately treat patients suffering from Atrial Fibrillation, or irregular heartbeats. By aiming to improve data quality and handling for clinicians treating patients with abnormal heart rates and rhythms, BioSig hopes to improve patient outcomes.
 

Contents of this tag:

This page references: